Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans

Background: Salvinorin-A is a terpene found in the leaves of the plant Salvia divinorum. When administered to humans, salvinorin-A induces an intense but short-lasting modified state of awareness, sharing features with those induced by the classical serotonin-2A receptor agonist psychedelics. However, unlike substances such as psilocybin or mescaline, salvinorin-A shows agonist activity at the kappa-opioid receptor rather than at the serotonin-2A receptor. Here, we assessed the involvement of kappa-opioid receptor and serotonin-2A agonism in the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans. Methods: We conducted a placebo-controlled, randomized, double-blind study with 2 groups of 12 healthy volunteers with experience with psychedelic drugs. There were 4 experimental sessions. In group 1, participants received the following treatment combinations: placebo+placebo, placebo+salvinorin-A, naltrexone+placebo, and naltrexone+salvinorin-A. Naltrexone, a nonspecific opioid receptor antagonist, was administered at a dose of 50mg orally. In group 2, participants received the treatment combinations: placebo+placebo, placebo+salvinorin-A, ketanserin+placebo, and ketanserin+salvinorin-A. Ketanserin, a selective serotonin-2A antagonist, was administered at a dose of 40mg orally. Results: Inhalation of 1mg of vaporized salvinorin-A led to maximum plasma concentrations at 1 and 2 minutes after dosing. When administered alone, salvinorin-A severely reduced external sensory perception and induced intense visual and auditory modifications, increased systolic blood pressure, and cortisol and prolactin release. These effects were effectively blocked by naltrexone, but not by ketanserin. Conclusions: Results support kappa opioid receptor agonism as the mechanism of action underlying the subjective and physiological effects of salvinorin-A in humans and rule out the involvement of a serotonin-2A-mediated mechanism.

• Publication year

  2016

• Venue

  International Journal of Neuropsychopharmacology

• Publication date

  2016-02-12

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/ijnp/pyw016PMID 26874330PMCID 4966277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans

  2016cited by this paper
• The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

  2015cited by this paper
• Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans

  2015cited by this paper
• κ‐Opioid receptors in the infralimbic cortex modulate the cardiovascular responses to acute stress

  2015cited by this paper
• Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

  2012cited by this paper
• Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

  2012cited by this paper
• Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

  2011cited by this paper
• Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca: A Comparative Study With d-Amphetamine

  2011cited by this paper
• Acute and post-acute behavioral and psychological effects of salvinorin A in humans

  2011cited by this paper
• Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents

  2010cited by this paper
• The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects

  2010cited by this paper
• Reward processing by the opioid system in the brain.

  2009cited by this paper
• Syntheses of novel high affinity ligands for opioid receptors.

  2009cited by this paper
• Unconditioned Behavioral Effects of the Powerful κ-Opioid Hallucinogen Salvinorin A in Nonhuman Primates: Fast Onset and Entry into Cerebrospinal Fluid

  2009influential reference
• Metabolic Changes in the Rodent Brain after Acute Administration of Salvinorin A

  2009cited by this paper
• Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys.

  2008cited by this paper
• Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans

  2008cited by this paper
• Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

  2007influential reference
• Effects of Salvinorin A, a κ-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High κ-Receptor Homology to Humans

  2007influential reference
• Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade

  2007cited by this paper
• Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers.

  2007cited by this paper
• Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

  2006cited by this paper
• Pattern of use and subjective effects of Salvia divinorum among recreational users.

  2006cited by this paper
• Endogenous κ-Opioid Receptor Systems Regulate Mesoaccumbal Dopamine Dynamics and Vulnerability to Cocaine

  2005cited by this paper
• Psychopharmacology of the hallucinogenic sage Salvia divinorum.

  2005cited by this paper
• Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study

  2004cited by this paper
• Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons.

  2003cited by this paper
• κ-Opioid Agonists Directly Inhibit Midbrain Dopaminergic Neurons

  2003cited by this paper
• Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist

  2002cited by this paper
• Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

  2002cited by this paper
• Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans

  2001cited by this paper
• The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans

  1998cited by this paper
• Repeated treatment with the selective kappa opioid agonist U‐69593 produces a marked depletion of dopamine D2 receptors

  1998cited by this paper
• Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action

  1998cited by this paper
• The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man

  1997influential reference
• Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A

  1995cited by this paper
• kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system.

  1995cited by this paper
• Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

  1994influential reference
• U50,488, a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats

  1994cited by this paper
• Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.

  1993cited by this paper
• Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

  1992cited by this paper
• Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex.

  1990cited by this paper
• Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man.

  1986cited by this paper
• Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint, Salvia divinorum

  1984cited by this paper
• Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.).

  1983cited by this paper
• Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum(Labiatae)

  1982cited by this paper
• Manual for the State-Trait Anxiety Inventory

  1970influential reference
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncited by this paper

• Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus

  2025cites this paper
• The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies

  2025cites this paper
• Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A

  2024cites this paper
• Hallucinations and Hallucinogens: Psychopathology or Wisdom?

  2023cites this paper
• The role of opioid transmission in music‐induced pleasure

  2022cites this paper
• The Altered States Database: Psychometric data from a systematic literature review

  2022cites this paper
• Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials

  2022cites this paper
• Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics

  2021cites this paper
• Therapeutic Use of Hallucinogens

  2021cites this paper
• The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A

  2021cites this paper
• Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.

  2021cites this paper
• Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects

  2021influential citation
• Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development.

  2021cites this paper
• Salvinorin A protects against methicillin resistant staphylococcus aureus-induced acute lung injury via Nrf2 pathway.

  2020cites this paper
• Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users

  2020cites this paper
• Neuroendocrine effects of naltrexone versus nalmefene in humans

  2020cites this paper
• Psychedelic drugs as a long-needed innovation in psychiatry

  2020cites this paper
• A global workspace, evolution-based model of the effect of psychedelics on consciousness.

  2020cites this paper
• The drug likeness analysis of anti-inflammatory clerodane diterpenoids

  2020cites this paper
• The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.

  2020cites this paper
• Endogenous Opiates and Behavior: 2017.

  2019cites this paper
• The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.

  2019cites this paper
• Salvinorin A attenuates early brain injury through PI3K/Akt pathway after subarachnoid hemorrhage in rat.

  2019cites this paper
• The Use of Salvia divinorum from a Mazatec Perspective

  2018cites this paper
• Studies with psychedelic drugs in human volunteers

  2017cites this paper
• Pharmacology and Structure-Activity Relationship of Natural Products With Psychoactive Effects From Salvia divinorum, Mitragyna speciosa, and Ayahuasca

  2017cites this paper
• “Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”

  2017cites this paper
• Medications for substance use disorders (SUD): emerging approaches

  2017cites this paper
• Clinical applications of hallucinogens: A review.

  2016cites this paper